These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 22634298)
21. Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells. Karimi K; Boudreau JE; Fraser K; Liu H; Delanghe J; Gauldie J; Xing Z; Bramson JL; Wan Y Mol Ther; 2008 Feb; 16(2):411-8. PubMed ID: 18059374 [TBL] [Abstract][Full Text] [Related]
22. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity. Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947 [TBL] [Abstract][Full Text] [Related]
23. Antitumor effects obtained by autologous Lewis lung cancer cell vaccine engineered to secrete mouse interleukin 27 by means of cationic liposome. Zhang J; Tian H; Li C; Cheng L; Zhang S; Zhang X; Wang R; Xu F; Dai L; Shi G; Chen X; Li Y; Du T; Deng J; Liu Y; Yang Y; Wei Y; Deng H Mol Immunol; 2013 Oct; 55(3-4):264-74. PubMed ID: 23522926 [TBL] [Abstract][Full Text] [Related]
24. Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity. Mai Y; Guo J; Zhao Y; Ma S; Hou Y; Yang J Cell Immunol; 2020 Aug; 354():104143. PubMed ID: 32563850 [TBL] [Abstract][Full Text] [Related]
25. Assessment of the Toll-like receptor 3 pathway in endosomal signaling. Matsumoto M; Funami K; Tatematsu M; Azuma M; Seya T Methods Enzymol; 2014; 535():149-65. PubMed ID: 24377923 [TBL] [Abstract][Full Text] [Related]
26. The role of surface charge density in cationic liposome-promoted dendritic cell maturation and vaccine-induced immune responses. Ma Y; Zhuang Y; Xie X; Wang C; Wang F; Zhou D; Zeng J; Cai L Nanoscale; 2011 May; 3(5):2307-14. PubMed ID: 21499635 [TBL] [Abstract][Full Text] [Related]
27. Cationic polypeptide micelle-based antigen delivery system: a simple and robust adjuvant to improve vaccine efficacy. Luo Z; Li P; Deng J; Gao N; Zhang Y; Pan H; Liu L; Wang C; Cai L; Ma Y J Control Release; 2013 Sep; 170(2):259-67. PubMed ID: 23742880 [TBL] [Abstract][Full Text] [Related]
28. Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects. Wang XD; Gao NN; Diao YW; Liu Y; Gao D; Li W; Wan YY; Zhong JJ; Jin GY World J Gastroenterol; 2015 Jul; 21(26):8052-60. PubMed ID: 26185376 [TBL] [Abstract][Full Text] [Related]
29. Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy. Su Q; Wang C; Song H; Zhang C; Liu J; Huang P; Zhang Y; Zhang J; Wang W J Mater Chem B; 2021 May; 9(18):3892-3899. PubMed ID: 33928989 [TBL] [Abstract][Full Text] [Related]
30. Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model. Vasievich EA; Ramishetti S; Zhang Y; Huang L Mol Pharm; 2012 Feb; 9(2):261-8. PubMed ID: 22142394 [TBL] [Abstract][Full Text] [Related]
31. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787 [TBL] [Abstract][Full Text] [Related]
32. Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice. Sultan H; Wu J; Kumai T; Salazar AM; Celis E Cancer Immunol Immunother; 2018 Jul; 67(7):1091-1103. PubMed ID: 29696308 [TBL] [Abstract][Full Text] [Related]
33. Tumor Cell-associated Exosomes Robustly Elicit Anti-tumor Immune Responses through Modulating Dendritic Cell Vaccines in Lung Tumor. Wang C; Huang X; Wu Y; Wang J; Li F; Guo G Int J Biol Sci; 2020; 16(4):633-643. PubMed ID: 32025211 [TBL] [Abstract][Full Text] [Related]
34. Vaccination with liposome--DNA complexes elicits enhanced antitumor immunity. U'Ren L; Kedl R; Dow S Cancer Gene Ther; 2006 Nov; 13(11):1033-44. PubMed ID: 16841080 [TBL] [Abstract][Full Text] [Related]
35. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. Salem ML; Kadima AN; Cole DJ; Gillanders WE J Immunother; 2005; 28(3):220-8. PubMed ID: 15838378 [TBL] [Abstract][Full Text] [Related]
36. Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity. Seya T; Shime H; Takeda Y; Tatematsu M; Takashima K; Matsumoto M Cancer Sci; 2015 Dec; 106(12):1659-68. PubMed ID: 26395101 [TBL] [Abstract][Full Text] [Related]
37. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. Gautier G; Humbert M; Deauvieau F; Scuiller M; Hiscott J; Bates EE; Trinchieri G; Caux C; Garrone P J Exp Med; 2005 May; 201(9):1435-46. PubMed ID: 15851485 [TBL] [Abstract][Full Text] [Related]
38. Neuropeptide signaling activates dendritic cell-mediated type 1 immune responses through neurokinin-2 receptor. Kitamura H; Kobayashi M; Wakita D; Nishimura T J Immunol; 2012 May; 188(9):4200-8. PubMed ID: 22474018 [TBL] [Abstract][Full Text] [Related]
39. Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant. Korsholm KS; Hansen J; Karlsen K; Filskov J; Mikkelsen M; Lindenstrøm T; Schmidt ST; Andersen P; Christensen D Vaccine; 2014 Jun; 32(31):3927-35. PubMed ID: 24877765 [TBL] [Abstract][Full Text] [Related]
40. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. Wang J; Saffold S; Cao X; Krauss J; Chen W J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]